SCHEMBL23409082

SCHEMBL23409082

CC(=O)c1ccc2nc(O)sc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
CDK5 Q00535 1/20 0.50
CDK5R1 Q15078 1/20 0.50
SMN1; SMN2 Q16637 5/20 0.49
DYRK1A Q13627 3/20 0.49
PIK3CA P42336 1/20 0.48
PIK3CB P42338 1/20 0.48
PIK3CG P48736 1/20 0.48
PI4KB Q9UBF8 1/20 0.48
KDM4E B2RXH2 2/20 0.46
NFKB1 P19838 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
LMNA P02545 1/20 0.46
GSK3B P49841 1/20 0.45
LDHA P00338 2/20 0.45
CA2 P00918 1/20 0.45
MAPT P10636 2/20 0.44
HTT P42858 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23480711 0.86 NPC1 (0.54) NPC1RAB9ASMN1; SMN2DYRK1ACA2
SCHEMBL18984451 0.84 SMN1; SMN2 (0.64) NPC1RAB9ASMN1; SMN2KDM4ENFKB1
SCHEMBL28247185 0.83 DYRK1A (0.60) NPC1RAB9ASMN1; SMN2DYRK1APIK3CA
SCHEMBL121976 0.83 RAB9A (0.52) NPC1RAB9ACDK5CDK5R1SMN1; SMN2
SCHEMBL6979665 0.83 NPC1 (0.72) NPC1RAB9ASMN1; SMN2LDHAMAPT
SCHEMBL1638828 0.81 RAB9A (0.59) NPC1RAB9ASMN1; SMN2KDM4ELMNA
SCHEMBL2000313 0.81 NPC1 (0.51) NPC1RAB9ACDK5CDK5R1SMN1; SMN2
SCHEMBL13881961 0.79 RAB9A (0.51) NPC1RAB9ACDK5CDK5R1SMN1; SMN2
SCHEMBL13412996 0.79 NPC1 (0.49) NPC1RAB9ACDK5CDK5R1SMN1; SMN2
SCHEMBL31003225 0.79 RAB9A (0.56) NPC1RAB9ACDK5CDK5R1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11484529-B2 Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production OP2 Drugs (FR) 2022-11-01 US disclosed
US-20210154175-A1 DESMETHYLANETHOLE TRITHIONE DERIVATIVES FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION OP2 Drugs (FR) 2021-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210154175-A1 DESMETHYLANETHOLE TRITHIONE DERIVATIVES FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION TXN2, ROS1, ERAL1 NPC1 1258/4885RAB9A 648/4885CDK5 3682/4885
US-11484529-B2 Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production TXN2, ROS1, ERAL1 NPC1 1258/4885RAB9A 648/4885CDK5 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.